Moderna: sales plummet in Q1
The laboratory posted an operating loss of $1,266 million, i.e. a net loss of $1,175 million, a far cry from the $79 million profit recorded twelve months earlier.
EPS came in at -$3.07 (though ahead of expectations), compared with +$0.2 a year earlier.
' As we anticipate the launches of our Spikevax 2024-2025 formula and RSV vaccine, we are demonstrating financial discipline and have intensified our efforts on the creation and use of AI technologies to further streamline operations and improve productivity,' commented Stéphane Bancel, Moderne's Chairman and CEO.
The company reaffirms its expectation of sales of around $4 billion for 2024 for its respiratory franchise, and now forecasts net sales of around $0.3 billion in the first half of the year, reflecting the seasonal nature of the respiratory business.
Copyright (c) 2024 CercleFinance.com. All rights reserved.
Go to the original article.
Contact us to request a correction